Woermann Lab

Research focus

ERC Starting Grant · 2024

Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancer

Pancreatic cancer is predicted to become the third leading cause of cancer-related death in Europe. Drug resistance to even the most effective anti-cancer-targeted therapies constitutes a major contributor to poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Kirsten rat sarcoma virus (KRAS) mutations are found in >90% of PDAC, being an important oncogenic driver. Although KRAS-targeted therapies have the potential to transform the clinical management of PDAC drastically, only a subset of patients respond, and resistance is frequent. The extent to which genomic and post-translational processes drive drug resistance remains largely unknown. Genomic analyses have identified the APOBEC…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.